News | October 18, 2021
WHO to take call on Covaxin's EUL on October 26th
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
HTL will build, validate and operate a botulinum manufacturing facility in the US
Subscribe To Our Newsletter & Stay Updated
